A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
Price : $35 *
At a glance
- Drugs Ivosidenib (Primary)
- Indications Acute myeloid leukaemia; Cholangiocarcinoma; Glioma; Myelodysplastic syndromes; Solid tumours
- Focus Pharmacokinetics
- Sponsors Agios Pharmaceuticals
- 26 Apr 2018 Status changed from recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 May 2018.
- 09 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 May 2018.